PI adds Optasia’s KneeAnalyzer to trial imaging service

By Gareth Macdonald

- Last updated on GMT

Related tags Rheumatoid arthritis Contract research organization

Perceptive Informatics (PI) has added Optasia’ KneeAnalyzer to its clinical offering, positioning itself for the anticipated surge in number of trials examining musculoskeletal drugs over the next few years

PI, the eClinical solutions subsidiary of US contract research organisation (CRO) Parexel, gained access to the KneeAnalyzer through an alliance it signed with Boston, US based software developer Optasia Medical

Demand for this type of drug is expected to increase dramatically over the next few years as improving global life expectancies mean a greater proportion of people are moving into the age groups most affected by such conditions.

A recent Espicom survey predicted that the market value for rheumatoid arthritis (RA) medications will double to $27bn by 2015 which, if accurate, will mean a significant increase in the number of trials examining drugs for the condition.

Recognition of this trend was a key motivation for the alliance according to PI VP of medical imaging Kenneth Faulkner, who told Outsourcing-pharma that: “Knee pain is extremely common in the population, as a result of both aging and disease, such as osteoarthritis.

The CDC estimates that six percent of all adults over age 30 suffer from symptomatic knee pain related to osteoarthritis and that 10 percent of those over 65 have symptomatic osteoarthritis at the knee. As a result, the interest in an accurate and precise measure of knee health is needed, both for research studies and clinical use​.”

He explained that the software measures “knee joint space​” as a marker of cartilage health which in “a medical-imaging based clinical trial, this capability allows Perceptive’s medical imaging experts to detect any changes faster and with fewer patients.”

Related news

Show more

Related products

show more

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

Related suppliers

Follow us


View more